Paris
France
125
2025-09-04
87
2025-08-19
These are the the leading inventors for applications assigned to CELLECTIS:
CELLECTIS based in Paris, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION
#2 | 2025-06-12METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTS
#3 | 2025-04-24ENGINEERING WHEAT WITH INCREASED DIETARY FIBER
#4 | 2025-01-30CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
#5 | 2024-10-31INHIBITORY CHIMERIC ANTIGEN RECEPTORS
#6 | 2024-09-19METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY
#7 | 2024-05-02 ✅ Patent 12,391,933 granted on 2025-08-19TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY
#8 | 2024-03-07CANOLA WITH HIGH OLEIC ACID
#9 | 2024-01-25 ✅ Patent 12,252,699 granted on 2025-03-18Method for generating t-cells compatible for allogenic transplantation
#10 | 2023-11-09CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS
#11 | 2023-06-29METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY
#12 | 2023-03-23 ✅ Patent 11,674,155 granted on 2023-06-13Sequential gene editing in primary immune cells
#13 | 2023-02-23METHODS FOR ENGINEERING HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY
#14 | 2023-02-16METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY
#15 | 2022-11-03 ✅ Patent 12,577,581 granted on 2026-03-17USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS
#16 | 2022-07-28 ✅ Patent 12,144,825 granted on 2024-11-19Cellular immunotherapy for repetitive administration
#17 | 2022-06-09USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS
#18 | 2022-02-03INHIBITORY CHIMERIC ANTIGEN RECEPTORS
#19 | 2022-01-13METHOD FOR THE GENERATION OF COMPACT TALE-NUCLEASES AND USES THEREOF
#20 | 2021-09-09 ✅ Patent 11,624,072 granted on 2023-04-11Canola with high oleic acid
#21 | 2021-07-22 ✅ Patent 11,274,316 granted on 2022-03-15Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
#22 | 2021-06-03 ✅ Patent 11,919,961 granted on 2024-03-05CD123 specific chimeric antigen receptors for cancer immunotherapy
#23 | 2021-05-20 ✅ Patent 11,959,091 granted on 2024-04-16Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
#24 | 2021-05-06 ✅ Patent 11,903,968 granted on 2024-02-20Engineered immune cells resistant to tumor microenvironment
#25 | 2021-03-18 ✅ Patent 12,012,607 granted on 2024-06-18Engineering wheat with increased dietary fiber
#26 | 2021-03-04 ✅ Patent 11,007,224 granted on 2021-05-18CD19 specific chimeric antigen receptor and uses thereof
#27 | 2021-03-04 ✅ Patent 11,077,144 granted on 2021-08-03CD19 specific chimeric antigen receptor and uses thereof
#28 | 2020-12-31 ✅ Patent 12,221,478 granted on 2025-02-11Targeted gene integration of CRS inhibitor genes for improved immune cells therapy
#29 | 2020-12-31 ✅ Patent 11,692,169 granted on 2023-07-04Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
#30 | 2020-12-17 ✅ Patent 11,767,512 granted on 2023-09-26Sequence specific reagents targeting CCR5 in primary hematopoietic cells
#31 | 2020-10-22 ✅ Patent 12,365,733 granted on 2025-07-22METHOD FOR IMPROVING PRODUCTION OF CAR T CELLS
#32 | 2020-09-10 ✅ Patent 11,891,614 granted on 2024-02-06Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
#33 | 2020-09-03 ✅ Patent 10,870,864 granted on 2020-12-22Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
#34 | 2020-07-30 ✅ Patent 12,209,125 granted on 2025-01-28Targeted gene integration of NK inhibitors genes for improved immune cells therapy
#35 | 2020-07-16 ✅ Patent 11,873,511 granted on 2024-01-16Targeted gene insertion for improved immune cells therapy
#36 | 2020-07-02 ✅ Patent 11,466,291 granted on 2022-10-11Sequential gene editing in primary immune cells
#37 | 2020-06-11 ✅ Patent 11,365,430 granted on 2022-06-21Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
#38 | 2020-02-13 ✅ Patent 11,479,782 granted on 2022-10-25Alfalfa with reduced lignin composition
#39 | 2019-12-26 ✅ Patent 11,498,971 granted on 2022-11-15BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#40 | 2019-11-07 ✅ Patent 11,220,683 granted on 2022-01-11Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains
#41 | 2019-10-17 ✅ Patent 11,136,566 granted on 2021-10-05Tale-protein scaffolds and uses thereof
#42 | 2019-08-29 ✅ Patent 11,312,972 granted on 2022-04-26Methods for altering amino acid content in plants through frameshift mutations
#43 | 2019-07-18 ✅ Patent 11,414,674 granted on 2022-08-16Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
#44 | 2019-07-18 ✅ Patent 10,517,896 granted on 2019-12-31Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
#45 | 2019-05-23 ✅ Patent 10,894,093 granted on 2021-01-19Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
#46 | 2019-01-24 ✅ Patent 10,550,402 granted on 2020-02-04Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes
#47 | 2019-01-10 ✅ Patent 11,820,996 granted on 2023-11-21Method for generating T-cells compatible for allogenic transplantation
#48 | 2019-01-03 ✅ Patent 10,988,541 granted on 2021-04-27CD123 specific chimeric antigen receptors for cancer immunotherapy
#49 | 2018-12-20METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY
#50 | 2018-11-15METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY
#51 | 2018-10-11 ✅ Patent 11,186,824 granted on 2021-11-30Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
#52 | 2018-10-11 ✅ Patent 10,752,670 granted on 2020-08-25Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
#53 | 2018-08-23 ✅ Patent 10,584,352 granted on 2020-03-10Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
#54 | 2018-08-23 ✅ Patent 10,988,542 granted on 2021-04-27Chimeric antigen receptors with integrated controllable functions
#55 | 2018-08-23 ✅ Patent 10,709,775 granted on 2020-07-14Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
#56 | 2018-07-19 ✅ Patent 10,836,998 granted on 2020-11-17Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
#57 | 2018-02-15 ✅ Patent 11,072,644 granted on 2021-07-27Inhibitory chimeric antigen receptors
#58 | 2018-01-25 ✅ Patent 10,363,270 granted on 2019-07-30Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy
#59 | 2018-01-11 ✅ Patent 11,014,989 granted on 2021-05-25Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
#60 | 2017-12-21 ✅ Patent 10,286,007 granted on 2019-05-14Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
#61 | 2017-10-12 ✅ Patent 10,472,613 granted on 2019-11-12Method for modulating car-induced immune cells activity
#62 | 2017-10-05 ✅ Patent 10,752,684 granted on 2020-08-25ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
#63 | 2017-09-28 ✅ Patent 10,759,868 granted on 2020-09-01Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
#64 | 2017-09-14 ✅ Patent 10,738,289 granted on 2020-08-11Tevi chimeric endonuclease and their preferential cleavage sites
#65 | 2017-08-10 ✅ Patent 10,544,201 granted on 2020-01-28ROR1 specific multi-chain chimeric antigen receptor
#66 | 2017-07-13ENGINEERING MAMMALIAN GENOME USING DNA-GUIDED ARGONAUTE INTERFERENCE SYSTEMS (DAIS)
#67 | 2017-06-29 ✅ Patent 10,316,101 granted on 2019-06-11BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#68 | 2017-06-29 ✅ Patent 9,944,709 granted on 2018-04-17CD123 specific chimeric antigen receptors for cancer immunotherapy
#69 | 2017-05-25 ✅ Patent 9,944,702 granted on 2018-04-17CD33 specific chimeric antigen receptors for cancer immunotherapy
#70 | 2017-03-23 ✅ Patent 10,837,024 granted on 2020-11-17Modifying messenger RNA stability in plant transformations
#71 | 2017-03-16 ✅ Patent 10,239,948 granted on 2019-03-26Method of engineering multi-input signal sensitive T cell for immunotherapy
#72 | 2017-03-09 ✅ Patent 10,196,608 granted on 2019-02-05Method for in situ inhibition of regulatory T cells
#73 | 2017-02-09 ✅ Patent 10,765,728 granted on 2020-09-08Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
#74 | 2016-12-15 ✅ Patent 10,813,951 granted on 2020-10-27Method of engineering chemotherapy drug resistant T-cells for immunotherapy
#75 | 2016-11-17 ✅ Patent 10,526,406 granted on 2020-01-07Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
#76 | 2016-10-13 ✅ Patent 11,198,856 granted on 2021-12-14Method for the generation of compact tale-nucleases and uses thereof
#77 | 2016-10-13 ✅ Patent 10,357,515 granted on 2019-07-23Method for generating batches of allogeneic T-cells with averaged potency
#78 | 2016-09-22 ✅ Patent 10,508,289 granted on 2019-12-17Rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
#79 | 2016-09-22 ✅ Patent 9,890,393 granted on 2018-02-13Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
#80 | 2016-08-04 ✅ Patent 10,378,026 granted on 2019-08-13RNA based method to obtain stably integrated retroviral vectors
#81 | 2016-06-30 ✅ Patent 9,855,297 granted on 2018-01-02Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
#82 | 2016-05-26 ✅ Patent 10,874,693 granted on 2020-12-29CD19 specific chimeric antigen receptor and uses thereof
#83 | 2016-05-12 ✅ Patent 10,087,453 granted on 2018-10-02Modified diatoms for biofuel production
#84 | 2016-05-12 ✅ Patent 10,000,746 granted on 2018-06-19LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
#85 | 2016-05-05 ✅ Patent 11,311,575 granted on 2022-04-26Methods for engineering highly active T cell for immunotherapy
#86 | 2016-05-05 ✅ Patent 11,304,975 granted on 2022-04-19Methods for engineering allogeneic and highly active t cell for immunotherapy
#87 | 2016-04-14 ✅ Patent 11,685,935 granted on 2023-06-27Compact scaffold of Cas9 in the type II CRISPR system
#88 | 2016-04-14 ✅ Patent 10,006,052 granted on 2018-06-26Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof
#89 | 2016-02-11 ✅ Patent 10,513,698 granted on 2019-12-24Potatoes with reduced cold-induced sweetening
#90 | 2015-12-24 ✅ Patent 10,301,637 granted on 2019-05-28Potatoes with reduced granule-bound starch synthase
#91 | 2015-11-05MEGANUCLEASE VARIANTS CLEAVING THE GENOME OF A PATHOGENIC NON-INTEGRATING VIRUS AND USES THEREOF
#92 | 2015-08-13 ✅ Patent 10,472,396 granted on 2019-11-12Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
#93 | 2015-08-06 ✅ Patent 10,378,007 granted on 2019-08-13Methods for modulating TAL specificity
#94 | 2015-07-23 ✅ Patent 10,815,500 granted on 2020-10-27Transcription activator-like effector (TALE) fusion protein
#95 | 2015-07-23 ✅ Patent 10,426,795 granted on 2019-10-01Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells
#96 | 2015-02-05 ✅ Patent 10,301,614 granted on 2019-05-28Method to overcome DNA chemical modifications sensitivity of engineered tale DNA binding domains
#97 | 2015-01-15METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPY
#98 | 2014-12-18 ✅ Patent 10,113,162 granted on 2018-10-30Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
#99 | 2014-08-21 ✅ Patent 9,540,623 granted on 2017-01-10Method for increasing the efficiency of double-strand-break induced mutagenesis
#100 | 2014-08-14MODULAR BASE-SPECIFIC NUCLEIC ACID BINDING DOMAINS FROM BURKHOLDERIA RHIZOXINICA PROTEINS
Also check out CELLECTIS's (Paris, France) applicant profile with 91 patent applications submitted.
10439 ⎘